Biologic Injections for Severe Psoriasis:
Are They Available in Chennai?

Published by Genesis Dermatology, Chennai
Medically reviewed by a board-certified dermatologist

Introduction

If you have been living with severe psoriasis for years, you already know that over the counter creams, oral tablets, and conventional treatments can only do so much. The plaques come back, the inflammation spreads, and the emotional toll compounds with every flare. What if there was a category of treatment that works precisely at the molecular level to switch off the signals that cause psoriasis in the first place? That treatment exists. It is called biologic therapy, and it is now available at an experienced skin doctor near you right here in Chennai.

Biologic injections have transformed the management of severe and moderate to severe plaque psoriasis globally over the last two decades. What was once only accessible in large metropolitan hospitals abroad is now well within reach for patients in Chennai seeking genuine long term relief. Genesis Dermatology brings this advanced level of care to patients across Porur, Ashok Nagar, OMR, and the wider Chennai region.

This blog is designed to give you a complete,medically grounded understanding of what biologic therapy is, how it works, which conditions it addresses, what the side effect profile looks like, and what you can realistically expect when you consult an experienced skin doctor near you for this treatment. Whether you are new to the term biologic or have done preliminary research and want to go deeper, this guide is built for you.

Key Takeaways

Biologic injections target specific immune pathways responsible for psoriasis, unlike conventional systemic treatments that suppress the entire immune system.
They are approved for moderate to severe plaque psoriasis and have shown skin clearance rates of 80 to 100 percent in clinical trials.
Biologics approved in India include IL-17, IL-23, IL-12/23, and TNF-alpha inhibitors, all available at Genesis Dermatology, Chennai.
An experienced skin doctor near you can determine your eligibility through a structured evaluation and safety screening.
Patients in Porur, Ashok Nagar, and OMR can access this treatment at Genesis Dermatology without traveling out of Chennai.
Long term safety data collected over 10 plus years supports the use of most approved biologics in adults.
Early intervention with biologics can prevent psoriatic arthritis progression in eligible patients.

Introduction
Key Takeaways
What Is Severe Psoriasis?
What Are Biologic Injections?
How Biologic Injections Work at the Molecular Level
Types of Biologic Injections Approved for Psoriasis in India
6.1 TNF-alpha Inhibitors
6.2 IL-12/23 Inhibitors
6.3 IL-17 Inhibitors
6.4 IL-23 Inhibitors
Who Is a Candidate for Biologic Therapy?
Issues Deeply Rectified by Biologic Injections
Clinical Outcomes and Effect of Biologic Therapy
Biologic Injections vs Conventional Treatments
Safety Profile and Side Effects
What to Expect Before, During, and After Treatment
Biologic Therapy and Psoriatic Arthritis
Cost and Accessibility in Chennai
Why Us? Genesis Dermatology for Patients in Porur, Ashok Nagar, and OMR
Frequently Asked Questions
Conclusion

What Is Severe Psoriasis?

Psoriasis is a chronic autoimmune skin disorder in which the immune system mistakenly accelerates the skin cell production cycle. In a healthy individual, skin cells take about 28 to 30 days to complete their life cycle. In someone with psoriasis, this cycle is compressed to just 3 to 4 days, resulting in the rapid buildup of cells on the skin surface that form thick, silvery-scaled plaques.

Severe psoriasis is clinically defined when the affected body surface area exceeds 10 percent, or when the disease significantly impacts quality of life, regardless of extent. The Body Surface Area (BSA), Psoriasis Area and Severity Index (PASI), and Dermatology Life Quality Index (DLQI) are the three standard tools dermatologists use to classify severity. A PASI score above 10 or a DLQI above 10 generally qualifies a patient for systemic or biologic treatment.

Severe psoriasis is not merely a skin problem. It is associated with a significantly elevated risk of developing psoriatic arthritis, cardiovascular disease, metabolic syndrome, depression, and inflammatory bowel disease. The systemic inflammation that drives skin flares is the same inflammation that damages joints and blood vessels over time. This is why an experienced skin doctor near you will always evaluate psoriasis as a full body inflammatory condition rather than an isolated cosmetic concern.

Common forms of severe psoriasis include:

Plaque psoriasis affecting more than 10 percent of the body surface
Erythrodermic psoriasis covering nearly the entire body surface with redness and scaling
Pustular psoriasis with widespread pus-filled blisters that are not caused by infection
Palmoplantar psoriasis causing debilitating involvement of palms and soles
Nail psoriasis with severe pitting, onycholysis, and subungual hyperkeratosis that restricts hand function
Scalp psoriasis extending beyond the hairline with thick plaques causing hair loss

What Are Biologic Injections?

Biologics are a class of medical treatments derived from living biological sources such as proteins, antibodies, and other naturally occurring molecules. Unlike conventional drugs that are chemically synthesized, biologics are manufactured through highly controlled biological processes involving cultured cells and recombinant DNA technology.

In the context of psoriasis, biologic injections are monoclonal antibodies or fusion proteins specifically engineered to identify and neutralize the exact cytokines and immune mediators that trigger psoriatic inflammation. Rather than broadly suppressing the immune system as older systemic drugs like methotrexate and cyclosporine do, biologics act on a single, well-defined target in the immune cascade.

This precision is what makes them so effective and, in many ways, safer than blanket immuno suppression. When you visit an experienced skin doctor near you and they recommend a biologic, they are pointing you toward a treatment that has been designed with extraordinary specificity for your disease mechanism.
Biologic injections for psoriasis are administered either subcutaneously (just under the skin) or intravenously (into a vein). Most approved for psoriasis are subcutaneous injections that patients can self-administer at home after initial training, though the first few doses are always given under clinical supervision.

To know more about Psoriasis in detail do read Its Here and Simplified! Eczema & Psoriasis Treatment in Chennai: A Dermatologist’s Complete Guide for Indian Skin

Also read The truth about Eczema in Adults vs. Children: Watch out How Symptoms & Treatment Differ in India

How Biologic Injections Work at the Molecular Level?

To understand why biologic injections are so effective in severe psoriasis, it helps to understand the immune pathway driving the disease. Psoriasis is mediated by the adaptive immune system, specifically by T-helper cells, dendritic cells, and a network of pro-inflammatory cytokines.

The process begins when plasmacytoid dendritic cells in the skin produce interferon-alpha in response to a perceived threat. This activates myeloid dendritic cells, which then release interleukin-12 (IL-12) and interleukin-23 (IL-23). IL-12 promotes the differentiation of naive T cells into Th1 cells, while IL-23 activates Th17 cells. Th17 cells are the primary drivers of psoriatic plaques, as they release IL-17A, IL-17F, and IL-22 which stimulate keratinocytes to proliferate at an accelerated rate, produce antimicrobial peptides, and recruit more neutrophils and inflammatory cells.

Simultaneously, TNF-alpha (tumor necrosis factor alpha) is released in large quantities, amplifying the inflammatory loop and sustaining the cycle of skin cell overproduction. Each class of biologic injection interrupts this pathway at a specific point:

TNF-alpha inhibitors bind to and neutralize TNF-alpha, reducing the overall inflammatory signal in both the skin and joints.
IL-12/23 inhibitors block the shared p40 subunit of both IL-12 and IL-23, interrupting both the Th1 and Th17 activation pathways simultaneously.
IL-17 inhibitors directly block IL-17A or its receptor, cutting off the final signaling molecule that instructs keratinocytes to overproduce.
IL-23 inhibitors target the p19 subunit unique to IL-23, selectively suppressing the Th17 pathway while leaving protective immune functions largely intact.

The selectivity of IL-23 and IL-17 inhibitors is particularly notable. Because they act on pathways specific to psoriatic inflammation rather than the entire immune system, they tend to carry a lower risk of opportunistic infections compared to older systemic agents. An experienced skin doctor near you will choose between these targets based on your disease profile, comorbidities, and prior treatment history.

Types of Biologic Injections Approved for Psoriasis in India

India’s Central Drugs Standard Control Organisation (CDSCO) has approved multiple biologic agents for the treatment of moderate to severe plaque psoriasis in adults. These are available through certified dermatology centers and specialty hospitals. Genesis Dermatology, as a specialized skin clinic in Chennai, works with the full range of approved biologics. When you consult an experienced skin doctor near you at our clinic, you benefit from a careful evaluation that matches you to the most appropriate agent.

6.1 TNF-alpha Inhibitors

Adalimumab (Humira and biosimilars): Administered as a subcutaneous injection every two weeks after a loading dose. Effective for both skin and joint disease. Strong long term safety data spanning over 15 years.
Etanercept (Enbrel and biosimilars): Given as weekly or twice weekly subcutaneous injections. Often used when other TNF inhibitors are not tolerated.
Infliximab (Remicade and biosimilars): Administered intravenously every 8 weeks after induction. Particularly useful for rapid clearance in acute severe presentations.

6.2 IL-12/23 Inhibitors

Ustekinumab (Stelara): Administered subcutaneously at week 0, week 4, and then every 12 weeks. Exceptional convenience with quarterly dosing after the initial phase. Very favorable long term tolerability profile.

6.3 IL-17 Inhibitors

Secukinumab (Cosentyx): The first approved IL-17A inhibitor for psoriasis in India. Administered weekly for 5 doses and then monthly. Achieves PASI 90 in over 70 percent of patients in clinical trials.
Ixekizumab (Taltz): A highly selective IL-17A inhibitor with rapid onset. Achieves near complete skin clearance (PASI 100) in a significant proportion of patients.
Bimekizumab (Bimzelx): Dual IL-17A and IL-17F inhibitor offering enhanced clearance compared to IL-17A inhibitors alone.

6.4 IL-23 Inhibitors

Guselkumab (Tremfya): A selective IL-23p19 inhibitor administered every 8 weeks after loading doses. Sustained clearance with excellent durability.
Risankizumab (Skyrizi): Quarterly dosing after induction. Highly selective and has shown superior PASI 90 and PASI 100 rates in head to head trials.
Tildrakizumab (Ilumetri): Approved in India and administered every 12 weeks. Good tolerability and sustained efficacy.

Who Is a Candidate for Biologic Therapy?

Not every psoriasis patient requires a biologic. The decision to initiate biologic therapy is based on a careful assessment by an experienced skin doctor near you, taking into account severity, quality of life impact, prior treatment response, and overall health status.

You are generally considered a candidate for biologic injections if one or more of the following criteria apply

Your PASI score is 10 or above, or your BSA involvement exceeds 10 percent
Your DLQI score is 10 or above, indicating significant quality of life impairment
You have failed to respond adequately to at least two conventional systemic treatments such as methotrexate, cyclosporine, or acitretin
You have psoriatic arthritis alongside skin psoriasis
You cannot tolerate conventional systemic treatments due to side effects or organ toxicity
Your psoriasis is located in high impact areas such as the face, genitals, palms, or soles that cause functional impairment even at lower BSA levels
You have rapid relapse after stopping conventional therapies

Before starting a biologic, your experienced skin doctor near you will conduct pre-treatment screening that typically includes tuberculosis testing (Mantoux and chest X-ray), hepatitis B and C serology, complete blood count, liver and kidney function tests, and a thorough review of your vaccination history. This screening is essential because biologics modulate immune function and latent infections can be reactivated.

Atopic Dermatitis – The truth about Atopic Dermatitis: Triggers, Flare Management & Long-Term Control

Issues Deeply Rectified by Biologic Injections

Biologic injections do not merely suppress symptoms. They address the root immunological dysfunction driving the disease and in doing so, provide resolution across a wide spectrum of disease manifestations. Below is a detailed analysis of the specific issues that biologic therapy corrects at a fundamental level.
Uncontrolled Keratinocyte Hyper proliferation

The most visible feature of psoriasis, the thick plaque, results from keratinocytes reproducing 10 times faster than normal. Biologics targeting IL-17 and IL-23 reduce the cytokine signals instructing keratinocytes to divide at this accelerated rate. Within weeks of starting therapy, the epidermal turnover rate normalizes, plaques thin, scaling reduces, and skin texture begins to restore. Patients who have carried thick plaques for years can achieve completely clear skin (PASI 100) with the right biologic.

Systemic Inflammation and Cardiovascular Risk

Severe psoriasis is associated with a 50 percent higher relative risk of major cardiovascular events compared to the general population, driven by chronic systemic inflammation. TNF-alpha inhibitors and IL-17 inhibitors have been shown in multiple observational studies to reduce circulating inflammatory markers such as CRP, IL-6, and fibrinogen. This anti-inflammatory effect extends beyond the skin and joints and may offer meaningful cardiovascular protection with long term use.

Psoriatic Plaque in Difficult Areas

Scalp psoriasis, genital psoriasis, palmoplantar psoriasis, and nail psoriasis are notoriously resistant to topical treatments. These areas have unique skin anatomy that limits drug penetration. Biologics work systemically, bypassing the topical absorption barrier entirely. Clinical trials have shown meaningful improvement in nail PASI scores and significant clearance in palmoplantar and genital psoriasis with secukinumab, ixekizumab, and guselkumab.

Psychological Burden and Depression

The bidirectional relationship between psoriasis and depression is well established. Chronic skin disease causes shame, social withdrawal, relationship strain, and occupational disruption. Depression further disregulates immune function, worsening flares. Biologics that achieve significant skin clearance demonstrate measurable improvements in DLQI, anxiety scores, and depression scales. Patients consistently report life-changing improvements in self-esteem and social functioning after achieving PASI 90 or above.

Fatigue and Inflammatory Arthralgia

Many patients with severe psoriasis experience fatigue, joint stiffness, and musculoskeletal aches even without a formal diagnosis of psoriatic arthritis. This reflects subclinical synovial inflammation driven by the same cytokines responsible for skin disease. Biologics, particularly TNF-alpha inhibitors and IL-17 inhibitors, reduce this systemic musculoskeletal inflammation, improving energy levels, morning stiffness, and functional capacity.

Cycle of Relapse and Remission

Conventional therapies often provide temporary relief followed by relapse when discontinued. Biologics, especially the IL-23 inhibitors, have demonstrated durable remission that persists even during drug-free intervals in some patients. Long term registry data from PSOLAR and BADBIR studies show that a meaningful percentage of biologic-treated patients maintain PASI 90 for periods of two to five years with continuous therapy.

Treatment Resistance to Prior Therapies

Many patients referred for biologic consideration have already failed methotrexate, phototherapy, and cyclosporine. This treatment failure can reflect individual pharmacogenomic differences or disease driven by pathways not addressed by these agents. By precisely targeting the upstream or downstream cytokines of the Th17 axis, biologics bypass the resistance mechanisms that limit conventional agents and achieve clearance where older treatments have consistently failed.

Clinical Outcomes and Effect of Biologic Therapy

The clinical evidence base for biologic therapy in severe psoriasis is among the strongest in all of dermatology. Multiple Phase III randomized controlled trials, long term extension studies, and real world registry data have been published, providing dermatologists and patients with a robust framework for expectations.

PASI Response Rates

PASI (Psoriasis Area and Severity Index) reduction is the primary efficacy measure in clinical trials. Response thresholds are defined as:

PASI 50: At least 50 percent reduction in plaque score
PASI 75: At least 75 percent reduction, considered the historical minimum acceptable response
PASI 90: At least 90 percent reduction, the current benchmark for modern biologic therapy
PASI 100: Complete clearance, achievable with the newest biologics in 30 to 60 percent of patients

To give you a concrete benchmark: ustekinumab achieves PASI 75 in approximately 70 percent of patients at week 28. Secukinumab achieves PASI 90 in over 70 percent. Risankizumab achieves PASI 90 in over 75 percent and PASI 100 in approximately 55 percent of patients in trial conditions. Real world data from registries shows sustained efficacy at rates close to trial results.

Speed of Response

IL-17 inhibitors such as secukinumab and ixekizumab are notably fast acting, with visible improvement in plaque thickness and scaling as early as 2 to 4 weeks. IL-23 inhibitors take slightly longer to reach peak effect but demonstrate superior durability. TNF-alpha inhibitors show meaningful improvement at 8 to 12 weeks. An experienced skin doctor near you will factor your urgency of response into the biologic selection decision.

Quality of Life Improvement

Consistent across all biologic classes is a dramatic improvement in DLQI scores. Patients achieving PASI 90 typically experience DLQI improvements from baseline scores of 15 to 25 down to 0 to 1, reflecting minimal impact of skin disease on everyday life. This translates directly into improved relationships, return to work, physical activity, and mental well being.

Long Term Durability

Long term extension data for most approved biologic extends to 5 to 10 years of follow up. Secukinumab 5-year data, risankizumab 3-year data, and adalimumab 10-year data all demonstrate maintenance of PASI 90 responses with continuous treatment and acceptable safety profiles. Drug survival rates (the proportion of patients remaining on a biologic at 5 years) are highest for IL-23 inhibitors, reflecting both superior efficacy and tolerability.

Biologic Injections vs Conventional Treatments: A Comparative Analysis

Parameter	Methotrexate	Cyclosporine	Biologic Injections
Mechanism	Broadly anti-inflammatory	Systemic immuno suppressant	Targeted cytokine blockade
PASI 75 rate	40 to 60 percent	50 to 70 percent	70 to 90 percent plus
PASI 90 rate	Rarely achievable	Occasionally	70 to 80 percent with modern agents
Long term use	Liver toxicity limits duration	Nephrotoxicity limits duration	Sustained for years with monitoring
Organ toxicity	Hepatic, hematologic	Renal, hypertension	Minimal organ toxicity
Psoriatic arthritis benefit	Moderate	Limited	Excellent
Quality of life impact	Moderate	Moderate	Transformative
Mode of administration	Weekly oral or injection	Daily oral	Subcutaneous, 1 to 12 weeks interval

Safety Profile and Side Effects

Biologic injections are among the most extensively studied drugs in dermatology. The safety data available from long term registries, post-marketing surveillance, and controlled trials provides a nuanced picture that allows dermatologists to make well-informed risk-benefit assessments for each individual patient.

Infections

The most commonly reported adverse effect across all biologic classes is upper respiratory tract infections, affecting approximately 10 to 15 percent of patients annually. These are generally mild and self-limiting. The rate of serious infections requiring hospitalization is low, reported at 1 to 2 per 100 patient-years in most registry data, which is comparable to rates seen with conventional systemic immuno suppression.

Reactivation of latent tuberculosis is the most important infection risk and is the primary reason pre-treatment TB screening is mandatory. With diligent screening and prophylactic treatment where indicated, this risk is substantially mitigated. IL-17 inhibitors carry a slightly higher risk of mucosal candidiasis (oral thrush) due to the role of IL-17 in mucosal immunity, but this is typically mild and responds to standard anti fungal treatment.

Injection Site Reactions

Mild redness, swelling, and discomfort at the injection site are common with subcutaneous biologics, particularly during the loading phase. These reactions typically diminish with continued treatment and rarely require discontinuation.

Inflammatory Bowel Disease

IL-17 inhibitors are generally avoided in patients with a history of or active inflammatory bowel disease, as they may worsen intestinal inflammation in susceptible individuals. This is a critical point of differentiation and is why consultation with an experienced skin doctor near you is essential before initiating any biologic.

Malignancy

Long term registry data does not show a significant increase in overall malignancy risk with most approved biologics compared to background population rates. Non-melanoma skin cancer risk may be marginally elevated with prolonged TNF-alpha inhibitor use, particularly in patients who have had prior phototherapy or immunosuppression. Your dermatologist will counsel you on this and arrange appropriate surveillance.

Pregnancy and Breastfeeding

Most biologic are not approved for use during pregnancy and are either classified as category B or carry insufficient safety data. Certolizumab pegol (a TNF inhibitor) has the most favorable pregnancy safety data and is sometimes used when treatment is essential. An experienced skin doctor near you will help plan pregnancy-safe treatment strategies for women of childbearing age.

What to Expect Before, During, and After Treatment

Before Starting Biologic Therapy

Your experienced skin doctor near you will conduct a comprehensive initial evaluation. This includes documenting your full psoriasis history, all prior treatments and their outcomes, a review of comorbidities, and a physical examination. Laboratory tests and imaging are ordered to establish baseline health parameters and screen for latent infections.

During Treatment

The initial loading phase involves more frequent injections, typically weekly for the first 4 to 5 doses depending on the biologic. After this, maintenance dosing follows a schedule ranging from every 2 weeks to every 12 weeks. Your dermatologist will monitor your response using PASI and DLQI scoring at scheduled intervals, typically at weeks 12, 24, and then every 6 months.
Blood tests are repeated at 3 to 6 month intervals to monitor for any changes in blood counts, liver parameters, or infection markers. Most patients notice visible improvement within the first 4 to 8 weeks, with maximal response typically achieved at 12 to 24 weeks.

After Achieving Clearance

Patients who achieve PASI 90 or PASI 100 face a decision about maintenance therapy. Stopping a biologic carries the risk of relapse, though the time to relapse varies by agent. IL-23 inhibitors demonstrate the most durable disease suppression after dose intervals are extended or treatment is paused. Your experienced skin doctor near you will guide the optimal maintenance strategy based on your individual disease behavior.

Biologic Therapy and Psoriatic Arthritis

Up to 30 percent of patients with moderate to severe plaque psoriasis will develop psoriatic arthritis, a destructive inflammatory arthritis affecting peripheral joints, the spine, and entheses. Early identification and treatment of psoriatic arthritis is critical because structural joint damage that occurs in the first two years can be irreversible.

Biologic injections offer a critical advantage in this context: many biologic approved for psoriasis also carry separate approval for psoriatic arthritis. TNF-alpha inhibitors and IL-17 inhibitors in particular have robust data demonstrating inhibition of radiographic joint damage progression alongside skin clearance.
When you consult an experienced skin doctor near you at Genesis Dermatology, joint symptoms including morning stiffness, swollen fingers (dactylitis), heel pain (enthesitis), and low back pain are systematically screened for. Early referral for rheumatological co-management is arranged where needed, and a biologic that addresses both skin and joint disease is preferentially selected.

Cost and Accessibility of Biologic Injections in Chennai

One of the most common concerns patients have is about the cost of biologic therapy. Originator biologics carry a high price tag globally. However, the Indian pharmaceutical market now has a substantial number of biosimilars approved by CDSCO that offer the same mechanism of action and comparable efficacy at a significantly lower cost.

For example, biosimilar adalimumab preparations are available at a fraction of the originator price. Biosimilars of etanercept, infliximab, and ustekinumab are also commercially available in India. This has made biologic therapy accessible to a broader section of the Indian patient population.

At Genesis Dermatology, we provide transparent counseling on all available brand options, including biosimilars, and help patients navigate insurance coverage, manufacturer patient assistance programs, and payment planning. An experienced skin doctor near you should not only prescribe appropriately but also help you access treatment within your financial context.

Patient assistance programs offered by biologic manufacturers including AbbVie, Novartis, Eli Lilly, and Johnson and Johnson are available in India and can substantially reduce out of pocket costs for eligible patients. Your experienced skin doctor near you at Genesis Dermatology can guide you through the application process for these programs.

Why Us? Genesis Dermatology for Patients in Porur, Ashok Nagar, and OMR

Advanced Biologic Care Is Now Right Where You Are
If you are living in Porur, Ashok Nagar, or OMR in Chennai and have been struggling with severe psoriasis that no cream or conventional tablet has been able to control, the answer is closer than you think. Genesis Dermatology is your trusted, experienced skin doctor near you, offering biologic injection therapy that was once only available in specialty centers abroad, right here in Chennai.

Why patients across Chennai choose Genesis Dermatology

Board-certified dermatologists with specialized training in biologic therapy and immune-mediated skin disorders
Comprehensive pre-biologic screening conducted in-clinic with fast-tracked laboratory coordination
Access to the full range of CDSCO-approved biologics including IL-17, IL-23, IL-12/23 inhibitors, and TNF-alpha inhibitors
Transparent cost counseling with guidance on biosimilar options and manufacturer assistance programs
Structured monitoring protocol with PASI and DLQI tracking at every follow-up visit
Integrated screening for psoriatic arthritis with rheumatology referral pathways in place
Personalized biologic selection based on your disease pattern, comorbidities, lifestyle, and treatment history
A compassionate care environment where your quality of life, not just your skin score, drives every decision

You deserve clear skin. You deserve an experienced skin doctor near you who understands the full scope of what psoriasis takes from you. Come to Genesis Dermatology. We are ready to help you reclaim your skin, your confidence, and your life.
Book your consultation today. Call us or walk in at our Chennai clinic serving Porur, Ashok Nagar, and OMR.

Frequently Asked Questions

Q1. How do I know if I need biologic injections for my psoriasis?

If your psoriasis affects more than 10 percent of your body surface area, your PASI score is 10 or above, or your daily life is significantly disrupted by the disease, you likely qualify for biologic therapy. The most reliable way to confirm eligibility is to consult an experienced skin doctor near you who can assess your PASI, DLQI, and treatment history and make a personalized recommendation. Patients who have failed at least two conventional systemic treatments are typically considered biologic candidates.

Q2. Are biologic injections safe for long term use?

Yes. The safety data for approved biologics in psoriasis now spans 10 to 15 years for some agents and demonstrates that most patients tolerate long term use well. The main monitoring requirements are for infection risk and blood parameter stability, both of which are addressed through routine laboratory check-ups every 3 to 6 months. An experienced skin doctor near you will review your safety parameters at each follow-up and adjust the treatment plan if needed.

Q3. How long does it take for biologic injections to show results in psoriasis?

Most patients notice visible improvement in plaque thickness and scaling within 4 to 8 weeks of starting therapy. IL-17 inhibitors are among the fastest acting, with some patients reporting meaningful clearance as early as 2 to 4 weeks. Peak response is typically achieved at 12 to 24 weeks depending on the biologic chosen. Your experienced skin doctor near you will set realistic timelines based on the specific agent selected for you.

Q4. Are biologic injections available and affordable in Chennai?

Yes. Several CDSCO-approved biologic and their Indian biosimilars are available in Chennai. Biosimilars offer significant cost savings compared to originator brands with comparable clinical outcomes. Genesis Dermatology provides counseling on all available options including manufacturer patient assistance programs that can further reduce costs. An experienced skin doctor near you at our clinic will help you identify the most cost-effective pathway to accessing biologic therapy.

Q5. Can biologic injections help with psoriatic arthritis in addition to skin psoriasis?

Absolutely. Several biologic classes, particularly TNF-alpha inhibitors and IL-17 inhibitors, are approved for both plaque psoriasis and psoriatic arthritis. They reduce joint inflammation, prevent structural damage, and improve physical function in addition to clearing skin plaques. If you have joint symptoms alongside psoriasis, an experienced skin doctor near you will assess whether a biologic with dual skin and joint indication is appropriate for your case.

Conclusion

Severe psoriasis is one of the most challenging chronic skin conditions to manage, not because effective treatments do not exist, but because finding the right one requires both advanced medical expertise and access to modern therapeutic options. Biologic injections represent a genuine paradigm shift in dermatology. They do not merely mask symptoms. They target the precise molecular dysfunction driving your disease and, in doing so, offer the possibility of near-complete or complete skin clearance that conventional treatments rarely achieve.

From correcting abnormal keratinocyte hyper proliferation to reducing systemic cardiovascular inflammation, from resolving treatment-resistant scalp and nail disease to protecting joints from long term damage, biologic therapy addresses psoriasis in its full biological complexity. The clinical evidence is extensive, the safety profile is well characterized, and the real world outcomes for patients mirror what controlled trials have demonstrated.

Most importantly, this level of care is available to you right now, without having to travel abroad or wait years for a referral. Genesis Dermatology is your experienced skin doctor near you in Chennai, equipped with the knowledge, the clinical protocols, and the full range of approved biologics to give you the best chance at the clear skin you deserve.
If you are in Porur, Ashok Nagar, OMR, or any part of Chennai and severe psoriasis has been holding you back, now is the time to take the next step. Consult an experienced skin doctor near you and discover what biologic therapy can do for your skin, your joints, and your life.

About Genesis Dermatology

Genesis Dermatology is a specialized dermatology clinic in Chennai offering expert diagnosis and treatment of all skin, hair, and nail conditions. Our team of experienced dermatologists is trained in evidence-based management of autoimmune skin disorders including psoriasis, eczema, vitiligo, and lupus. We combine advanced therapeutics with compassionate care to deliver outcomes that truly change lives. Serving patients across Porur, Ashok Nagar, OMR, and all of Chennai.

This blog is for informational purposes only and does not constitute medical advice. Please consult a qualified dermatologist for diagnosis and treatment.
Copyright 2026 Genesis Dermatology, Chennai. All rights reserved.

Biologic Injections for Severe Psoriasis: Are They Available in Chennai?